Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics (Premium)
$25.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actelion Ltd Closes Acquisition Of Privately-held Ceptaris Therapeutics


Thursday, 19 Sep 2013 01:00am EDT 

Actelion Ltd announced that it has concluded the acquisition of Ceptaris Therapeutics, Inc. following US Food and Drug Administration (FDA) approval for Valchlor (mechlorethamine) gel 0.016% and the satisfaction of additional closing conditions. Ceptaris was a privately held, specialty pharmaceutical company established to develop the gel formulation of mechlorethamine for the treatment of early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The terms of the acquisition were not disclosed. 

Company Quote

108.8
-1.2 -1.09%
21 Aug 2014